TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30052571

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation (10 billion colony-forming units daily for 6 months)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no LGG supplementation)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study: 28739766

Group type: EXPERIMENTAL
Intervention: Biliary stent implantation combined with intraluminal brachytherapy by 125I seeds articles
Number of subjects: 50

Group type: COMPARATOR
Intervention: Biliary stent implantation only
Number of subjects: 50
Study: 25307622

Group type: EXPERIMENTAL
Intervention: Local echocardiographic measurements of fractional shortening (FS)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Central echocardiographic measurements of fractional shortening (FS)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Local categorization of LV function
Number of subjects: 59
Study: 23161902

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg every 4 weeks (q4wks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg every 4 weeks (q4wks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg or 100 mg (from week 24)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab (50 mg or 100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21606190

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Regular Human Insulin (HI)
Number of subjects: 13
Study: 21050483

Group type: EXPERIMENTAL
Intervention: Animal Fun program (teacher delivered universal program incorporating animal actions)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control schools (six control schools)
Number of subjects: 520
Study: 17169543

Group type: EXPERIMENTAL
Intervention: Kytta-Salbe f (comfrey root extract ointment), 6g daily application (3 x 2g) for 3 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Kytta-Salbe f (comfrey root extract ointment)
Number of subjects: 220
Study: 14741065

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (Group R)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (Group B)
Number of subjects: 62
Study: 12185118

Group type: EXPERIMENTAL
Intervention: Wearing a facemask during cataract surgery
Number of subjects: 221

Group type: COMPARATOR
Intervention: Not wearing a facemask during cataract surgery
Number of subjects: 221
Study: 9748710

Group type: EXPERIMENTAL
Intervention: Immediate release enteric-coated test formulation containing aesculus extract, 50 mg escin b.i.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prolonged-release reference preparation, 50 mg escin b.i.d.
Number of subjects: 18
Study: 7661265

Group type: EXPERIMENTAL
Intervention: Washout with lactated Ringer's solution
Number of subjects: 23
Study: 2501877

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Ftorafur + Orimeten
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cyclophosphamide + Ftorafur + placebo
Number of subjects: 16
Study: 351814

Group type: EXPERIMENTAL
Intervention: Etidocaine 0.5% with epinephrine 1:200,000
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lidocaine 1% with epinephrine 1:200,000
Number of subjects: 48

Group type: COMPARATOR
Intervention: Etidocaine 0.5% plain
Number of subjects: 48
Study: 30786877

Group type: EXPERIMENTAL
Intervention: Current regular drinking (at least weekly)
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Current regular drinking in urban areas
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Current regular drinking in rural areas
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Current regular drinking at resurvey
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Ex-regular drinkers
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking (> 60 g/session)
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking in rural areas
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking in urban areas
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Heavy drinking episodes among younger men (born in the 1970s)
Number of subjects: 512000

Group type: EXPERIMENTAL
Intervention: Health-related risk factors among heavy drinkers
Number of subjects: 512000
Study: 28928190

Group type: EXPERIMENTAL
Intervention: RADICALS (interdisciplinary model of care)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 280
Study: 26008653

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Land-mark technique
Number of subjects: 200
Study: 23159302

Group type: EXPERIMENTAL
Intervention: 30-minute educational program
Number of subjects: 877

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 877
Study: 21728389

Group type: EXPERIMENTAL
Intervention: ELIOT (21 Gy single dose)
Number of subjects: 178

Group type: COMPARATOR
Intervention: EBRT (50 Gy whole breast + 10 Gy boost)
Number of subjects: 178
Study: 19819114

Group type: COMPARATOR
Intervention: haloperidol (1‐4 mg/d)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: amisulpride (200‐800 mg/d)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: olanzapine (5‐20 mg/d)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: quetiapine (200‐750 mg/d)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: ziprasidone (40‐160 mg/d)
Number of subjects: 498
Study: 16414127

Group type: EXPERIMENTAL
Intervention: Mucosal flap sealing over the operation site
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (operation site left uncovered)
Number of subjects: 39
Study: 12782919

Group type: EXPERIMENTAL
Intervention: Continuous intestinal levodopa infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral sustained-release levodopa preparation
Number of subjects: 12
Study: 10957888

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg 12-hourly for 10 days
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Roxithromycin 150 mg 12-hourly for 10 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Erythromycin stearate 500 mg 6-hourly for 10 days
Number of subjects: 86
Study: 9323819

Group type: EXPERIMENTAL
Intervention: Surgical repair of tetralogy of Fallot in adulthood
Number of subjects: 104
Study: 8406655

Group type: EXPERIMENTAL
Intervention: Sodium reduction intervention (dietary sodium to 80 mmol/24 h)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Sodium reduction intervention
Number of subjects: 744
Study: 3535741

Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride (450 mg/m2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 75
Study: 30053397

Group type: EXPERIMENTAL
Intervention: ThuFLEP
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HoLEP
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MEP
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Laser EEP (HoLEP, ThuFLEP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Initial stages of training (first 20 surgeries)
Number of subjects: 90
Study: 26227799

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 350

Group type: COMPARATOR
Intervention: amisulpride
Number of subjects: 350
Study: 25016533

Group type: EXPERIMENTAL
Intervention: Total energy consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity-related energy expenditure (AREE)
Number of subjects: 0
Study: 23095630

Group type: EXPERIMENTAL
Intervention: Dunhill (DUN)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Hemithyroidectomy (HMT)
Number of subjects: 118
Study: 19730942

Group type: EXPERIMENTAL
Intervention: 10% Xylocaine pump spray plus plain Strepsils
Number of subjects: 191

Group type: COMPARATOR
Intervention: Strepsils Dual Action anesthetic lozenge plus distilled water spray
Number of subjects: 191
Study: 18979599

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (n = 44)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Neutral liquid soap (n = 49)
Number of subjects: 93
Study: 15896585

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg and propofol 1 mg/kg (group 1 n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketamine 0.5 mg/kg and propofol 1 mg/kg (group 2 n = 20)
Number of subjects: 40
Study: 12169868

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of losartan 25 mg and enalapril 10 mg
Number of subjects: 51
Study: 9802752

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 7715987

Group type: EXPERIMENTAL
Intervention: CMV immunoglobulin (CMVIG) 150 mg/kg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: CMV immunoglobulin (CMVIG)
Number of subjects: 183
Study: 2692965

Group type: EXPERIMENTAL
Intervention: Diane‐35 for 6 cycles
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Microgynon for 6 cycles
Number of subjects: 50
Study: 879708

Group type: EXPERIMENTAL
Intervention: Thompson endoprosthesis with intensive physical therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Thompson endoprosthesis with routine physical therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Internal fixation with intensive physical therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Internal fixation with routine physical therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups (Thompson endoprosthesis and internal fixation)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Number of subjects: 87
Study: 31227804

Group type: EXPERIMENTAL
Intervention: Olive oil (OO)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Palm olein (PO)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cocoa butter (CB)
Number of subjects: 38
Study: 29778130

Group type: EXPERIMENTAL
Intervention: Increasing blood flow rate by 25 rpm for the first two weeks and 50 rpm for the second two weeks during hemodialysis.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard blood flow rate).
Number of subjects: 60
Study: 27461166

Group type: EXPERIMENTAL
Intervention: Daclizumab 150 mg subcutaneous every 4 weeks
Number of subjects: 410
Study: 23838625

Group type: EXPERIMENTAL
Intervention: Acceleration training (AT) with vibration stimulus (frequency, 40 Hz; amplitude, 2-4 mm)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (Con) without vibration stimulus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acceleration training (AT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 18
Study: 22070452

Group type: EXPERIMENTAL
Intervention: Specialist supportive care plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19674354

Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline solution and salbutamol
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (4.0 mL normal (0.9%) saline with 2.5 mg salbutamol)
Number of subjects: 93
Study: 17510676

Group type: EXPERIMENTAL
Intervention: 13C‐enriched 6% CHO drink
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15687232

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by purged autologous stem-cell transplantation
Number of subjects: 172

Group type: COMPARATOR
Intervention: Chemotherapy and interferon (cyclophosphamide, doxorubicin, teniposide, prednisone, and interferon)
Number of subjects: 172
Study: 12297768

Group type: EXPERIMENTAL
Intervention: Balloon-occluded endoscopic injection sclerotherapy (BO-EIS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration (B-RTO)
Number of subjects: 20
Study: 10595697

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Doxazosin standard
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS and Doxazosin standard
Number of subjects: 392
Study: 8758250

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFO) administered as 6-9 g/m2 over 15 days, repeated every 3 weeks for up to 16 courses, either as a continuous 72 h infusion or as three bolus doses of 3 g/m2 on consecutive days.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFO) administration with changes in metabolism measured during early and late courses.
Number of subjects: 15
Study: 1883969

Group type: EXPERIMENTAL
Intervention: Epoetin beta (100 U/kg thrice weekly for 6 weeks, then 50 to 150 U/kg thrice weekly for 6 weeks)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Epoetin beta after crossover from placebo
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 7037302

Group type: EXPERIMENTAL
Intervention: Systematic turning every 2 hours for the first 24 hours post-surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: Supine position for the first 24 hours post-surgery
Number of subjects: 35
Study: 31770245

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise without behavioral approach (NSE)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with behavioral approach (NSEB)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Physical activity prescription (PPA)
Number of subjects: 188
Study: 28887907

Group type: EXPERIMENTAL
Intervention: WBB beverage (25 g freeze dried WBB powder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study: 26475662

Group type: EXPERIMENTAL
Intervention: Personalized exercise rehabilitation (12-month intervention, twice a week, 60 minutes each session)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard clinical care (control group)
Number of subjects: 120
Study: 24106924

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg q.d. for 12 weeks
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 936

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 936
Study: 22249353

Group type: EXPERIMENTAL
Intervention: Tailored treatment strategy using the Multiplate analyzer
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard administration of 75 mg clopidogrel
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Multiplate‐tailored therapy
Number of subjects: 192
Study: 19781899

Group type: EXPERIMENTAL
Intervention: Isomaltulose-based enteral formula (IF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard feeding formula (SF)
Number of subjects: 8
Study: 18046053

Group type: EXPERIMENTAL
Intervention: Red Bull energy drink (2 mg/kg body mass of caffeine)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (isoenergetic, isovolumetric, noncaffeinated)
Number of subjects: 15
Study: 16128596

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 90
Study: 11911517

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with bipolar interferential current (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with low-frequency current (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both stimulation groups (A and B)
Number of subjects: 30
Study: 10194083

Group type: EXPERIMENTAL
Intervention: D0870 (azole)
Number of subjects: 114
Study: 8789567

Group type: EXPERIMENTAL
Intervention: Alcohol (1.2 g alcohol.kg‐1 body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study: 2303280

Group type: EXPERIMENTAL
Intervention: Desipramine (125 mg p.o.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6803692

Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day for 4 months)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (4 months after bromocriptine)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bromocriptine and Placebo
Number of subjects: 17
Study: 31288354

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 30 seconds
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 1.0 minute
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 2.0 minutes
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine for 3.5 minutes
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 400
Study: 26715522

Group type: EXPERIMENTAL
Intervention: Iron-treated group (50 mg elemental iron/daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 70
Study: 25168031

Group type: EXPERIMENTAL
Intervention: E‐cigarette use
Number of subjects: 4660
Study: 24712716

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 17822748

Group type: EXPERIMENTAL
Intervention: Cisplatin-ifosfamide and mesna (CIM)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Whole abdominal irradiation (WAI)
Number of subjects: 206
Study: 15195691

Group type: EXPERIMENTAL
Intervention: Nicardipine solution (20 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nicardipine tablets (20 mg)
Number of subjects: 24
Study: 11214632

Group type: EXPERIMENTAL
Intervention: Heparinized EVD catheters
Number of subjects: 198

Group type: COMPARATOR
Intervention: Unheparinized EVD catheters
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Heparinized EVD catheters in patients with subarachnoid hemorrhages
Number of subjects: 198

Group type: COMPARATOR
Intervention: Unheparinized EVD catheters in patients with subarachnoid hemorrhages
Number of subjects: 198
Study: 9433410

Group type: EXPERIMENTAL
Intervention: Ileocolonoscopy and biopsy
Number of subjects: 24
Study: 8366184

Group type: EXPERIMENTAL
Intervention: Lovastatin (80 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2871952

Group type: EXPERIMENTAL
Intervention: GRF 1-29 (100 or 50 micrograms as i.v. bolus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine (1.2 mg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide (MCP, 10 mg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thymoxamine (THYM, 210 micrograms/min, 150 min infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TRH administration
Number of subjects: 0
Study: 31127363

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including continuing medical education, distribution of guidelines, and educational outreach visits in Berlin (intervention region)
Number of subjects: 1900

Group type: COMPARATOR
Intervention: No specific interventions in Hamburg (control region)
Number of subjects: 1900
Study: 28986719

Group type: EXPERIMENTAL
Intervention: 3D imaging system
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D imaging system
Number of subjects: 0
Study: 25601942

Group type: EXPERIMENTAL
Intervention: JENVAC (2 doses, 28 days apart)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SA-14-14-2 (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JENVAC (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JENVAC (2 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JENVAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JENVAC and SA-14-14-2
Number of subjects: 0
Study: 24664356

Group type: EXPERIMENTAL
Intervention: Graded Response Model (GRM)
Number of subjects: 1296
Study: 23131813

Group type: EXPERIMENTAL
Intervention: Green tea (1.0 g sachets, 3 cups per day for 60 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 19526157

Group type: EXPERIMENTAL
Intervention: Mannitol infusion (0.5 gm/kg) during ESWL
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 38
Study: 17333451

Group type: EXPERIMENTAL
Intervention: PTH(1‐84)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 119
Study: 15041612

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 36
Study: 11346336

Group type: EXPERIMENTAL
Intervention: 6.5 mg/m(2) per day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 300 mg/m(2) per day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Above 300 mg/m(2) per day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Crossover from 6.5 mg/m(2) per day to higher doses
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Drug-related adverse effects
Number of subjects: 58
Study: 9006882

Group type: EXPERIMENTAL
Intervention: Local hand cooling (5‐7 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined arterial occlusion and local cooling
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arterial occlusion (3 min)
Number of subjects: 10
Study: 8485071

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg, sublingual)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3688282

Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (double-blind manner)
Number of subjects: 2
Study: 29183035

Group type: EXPERIMENTAL
Intervention: RR with activated navigation system
Number of subjects: 42

Group type: COMPARATOR
Intervention: RR without activated navigation system
Number of subjects: 42
Study: 27218476

Group type: EXPERIMENTAL
Intervention: High concentration EtOH (targeted BrAC = 0.100 g/dl)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low concentration EtOH (targeted BrAC = 0.040 g/dl)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24274088

Group type: EXPERIMENTAL
Intervention: Death reminder
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2